Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
A 44-year-old Woman with Rapidly Progressive Weakness and Ophthalmoplegia
Neurol 85:e22-e27, Schreck, K.C.,et al, 2015
The Spectrum of Acute Encephalitis
Neurol 84:359-366, Singh, T.D.,et al, 2015
Effects of Golden Hour Thrombolysis
JAMA Neurol 72:25-30,9, Ebinger, M.,et al, 2015
Implementing a Mobile Stroke Unit Program in the United States
JAMA Neurol 72:229-234, Rajan, S.,et al, 2015
Screening with MRI for Accurate and Rapid Stroke Treatment
Neurol 84:2438-2444, 2394, Shah, S.,et al, 2015
Significant Period Between Presentation and Diagnosis in Basilar Artery Occlusion
Stroke 46:e79-e81, Organek, N.,et al, 2015
Varicella Zoster Virus Meningoencephalitis Presenting with Elsberg Syndrome without a Rash in an Immunocompetent Patient
Intern Med 54:2065-2067, Abe, M.,et al, 2015
4.5-Hour Time Window for Intravenous Thrombolysis with Recombinant Tissue-Type Plasminogen Activator is Established Firmly
Stroke 45:912-913,916, Schellinger, P.D. & Kohrmann, M., 2014
The 4.5-HourTime Window for Intravenous Thrombolysis with Intravenous Tissue-Type Plasminogen Activator is Not Firmly Established
Stroke 45:915-915,916, Wechsler, L.R., 2014
A Case-Controlled Comparison of Thrombolysis Outcomes Between Wake-Up and Known Time of Onset Ischemic Stroke Patients
Stroke 44:2226-2231, Manawadu, D.,et al, 2013
Continuous and Routine EEG in Intensive Care
Neurol 81:2002-2008, Ney, J.P.,et al, 2013
Results of Intravenous Thrombolysis within 4.5 to 6 Hours and Updated Results within 3 to 4.5 Hours of Onset of Acute Ischemic Stroke Recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR)
JAMA Neurol 70:837-844, Ahmed, N.,et al, 2013
Association of Prehospital Advanced Airway Management with Neurologic Outcome and Survival in Patients with Out-of-Hospital Cardiac Arrest
JAMA 309:257-266,285, Hasegawa, K.,et al, 2013
Prehospital Thrombolysis in Acute Stroke
Neurol 80:163-168, Weber, J.,et al, 2013
Treatment Decisions after Severe Stroke
Stroke 43:3405-3408, Creutzfeldt, C. & Holloway, R., 2012
Sleep Apnea
NEJM 367:e33, Kuipers, A., 2012
A Pragmatic Approach Using Magnetic Resonance Imaging to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial
Stroke 43:2331-2335, Song, S.S.,et al, 2012
Hemostatic Therapy Should be Used for Acute Treatment of Anticoagulation-Related Intracerebral Hemorrhage
Stroke 43:2535-2536,2539, Diringer, M. & Zazulia, A.R., 2012
Hemostatic Therapy Should not be Used for Acute Treatment of Anticoagulation-Related Intracerebral Hemorrhage
Stroke 43:2537-2538,2539, Stapf, C., 2012
The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012
Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012
Stroke Recurrence in Children with Congenital Heart Disease
Ann Neurol 72:103-111, Rodan, L.,et al, 2012
Asymmetric Pattern of Cerebrovascular Lesions in Patients after Left Ventricular Assist Device Implantation
Stroke 43:872-874, Kato,T.S.,et al, 2012
Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Helicopter Transport of Stroke Patients and Its Influence on Thrombolysis Rates
Stroke 42:1295-1300, Reiner-Deitemyer, V.,et al, 2011
Effects of Extending the Time Window of Thrombolysis to 4.5 Hours Observations in the Swedish Stroke Register (Riks-Stroke)
Stroke 42:2492-2497, Asplund, K.,et al, 2011
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
NEJM 364:2187-98, 2256, Smith, C.R.,et al, 2011
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Clinical and Genetic Spectrum of Mitochondrial Neurogastrointestinal Encephalomyopathy
Brain 134:3326-3332, Garone, C.,et al, 2011
Prediction of Respiratory Insufficiency in Guillain-Barr� Syndrome
Arch Neurol 67:781-787, Walgaard,C.,et al, 2010
Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage
Stroke 41:2860-2866, Majeed,A.,et al, 2010
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
Stroke 41:2108-2129, Morgenstern,L.B.,et al, 2010
The "Golden Hour" and Acute brain Ischemia: Presenting Features and Lytic Therapy in >30000 Patients Arriving Within 60 Minutes of Stroke Onset
Stroke 41:1431-1439, Saver,J.L., et al, 2010
Ultraearly Thrombolysis in Acute Ischemic Stroke Is Associated with Better Outcome and Lower Mortality
Stroke 41:712-716, Strbian,D., et al, 2010
Fluid-Attenuated Inversion Recovery Evolution Within 12 Hours from Stroke Onset: A Reliable Tissue Clock?
Stroke 41:250-255, 197, Ebinger,M.,et al, 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Time to Treatment With Intravenous Alteplase and Outcome in Stroke: An Updated Pooled Analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
Lancet 375:1695-1703, 1667, Lees, K.R., et al, 2010
Treatment Decisions After Brain Injury - Tensions Among Quality, Preference, and Cost
NEJM 362:1757-1759, Holloway,R.G. &Quill,T.E., 2010
Remote Supervision of IV-tPA for Acute Ischemic Stroke by Telemedicine or Telephone Before Transfer to a Regional Stroke Center Is Feasible and Safe
Stroke 41:e18-e24, Pervez,M.,et al, 2010
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009
Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009
Anti-N-Methyl-D-Aspartate Receptor (NHMDAR) Encephalitis in Children and Adolescents
Ann Neurol 66:11-18,1, Florance,N.R.,et al, 2009
Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review)
Neurol 73:1218-1226, Miller,R.G.,et al, 2009
4.5 Hours: The New Time Window for Tissue Plasminogen Activator in Stroke
Stroke 40:2266-2267, Davis,S.M. &Donnan,G.A., 2009
Neurologic Prognosis After Cardiac Arrest
NEJM 361:605-611, Young,G.B., 2009
Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009